Last reviewed · How we verify

Nifurtimox (Lampit, BAYA2502) — Competitive Intelligence Brief

Nifurtimox (Lampit, BAYA2502) (Nifurtimox (Lampit, BAYA2502)) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nitrofuran antiparasitic. Area: Infectious Disease / Parasitology.

phase 3 Nitrofuran antiparasitic Parasite DNA and proteins (via reactive oxygen species generation) Infectious Disease / Parasitology Small molecule Live · refreshed every 30 min

Target snapshot

Nifurtimox (Lampit, BAYA2502) (Nifurtimox (Lampit, BAYA2502)) — Bayer. Nifurtimox is a nitrofuran compound that generates reactive oxygen species to kill parasites, particularly effective against Trypanosoma cruzi.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Nifurtimox (Lampit, BAYA2502) TARGET Nifurtimox (Lampit, BAYA2502) Bayer phase 3 Nitrofuran antiparasitic Parasite DNA and proteins (via reactive oxygen species generation)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nitrofuran antiparasitic class)

  1. Bayer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nifurtimox (Lampit, BAYA2502) — Competitive Intelligence Brief. https://druglandscape.com/ci/nifurtimox-lampit-baya2502. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: